Idiotype protein-pulsed dendritic cells produce strong anti-myeloma effects after syngeneic stem cell transplantation in mice

Bone Marrow Transplantation

Volumn 29, Issue 3, 2002, Pages 213-221

  Zeis, M ^a   Frenzke, H ^a   Schmitz, N ^a   Uharek, L ^a   Steinmann, J ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Complementary determining region; Dendritic cells; Idiotype; Immunoglobulin

Indexed keywords

CD8 ANTIGEN; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN IDIOTYPE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DENDRITIC CELL; HEMATOPOIETIC STEM CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INOCULATION; ISOGRAFT; MOUSE; MOUSE STRAIN; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; PERITONEUM; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SURVIVAL TIME; T LYMPHOCYTE ACTIVATION; VACCINATION; WHOLE BODY RADIATION;

ANIMALS; ANTIGENS, NEOPLASM; CELL CULTURE TECHNIQUES; COMBINED MODALITY THERAPY; DENDRITIC CELLS; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOGLOBULIN IDIOTYPES; IMMUNOTHERAPY, ADOPTIVE; MICE; MICE, INBRED BALB C; MULTIPLE MYELOMA; SURVIVAL RATE; T-LYMPHOCYTES, CYTOTOXIC; TRANSPLANTATION, ISOGENEIC; TUMOR CELLS, CULTURED;

EID: 0036187858     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703327     Document Type: Article

References (34)

1. Multiple myeloma
2. Autologous and allogeneic transplants for multiple myeloma
3. A prospective, randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma
4. High-dose busulfan and cyclophosphamide are an effective conditioning regimen for allogeneic bone marrow transplantation in chemosensitive multiple myeloma
5. Autoimmune-like antibodies to the ligand-binding sites of myeloma proteins
6. Myeloma proteins as tumor-specific transplantation antigens
7. Idiotype vaccination against murine B cell lymphoma: Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits
8. Transfer of specific immunity to B-cell lymphoma with syngeneic bone marrow in mice: A strategy for using autologous marrow as an anti-tumor therapy
9. Naive CD4+ T cells confer idiotype-specific tumor resistance in the absence of antibodies
10. Naive idiotypespecific CD4+ T cells and immunosurveillance of B-cell tumors
11. The role of idiotype-specific, CD4+ T cells in tumor resistance against major histocompatibility complex class II molecule negative plasmacytoma cells
12. Anti-tumor activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo
13. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes
14. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity
15. Bone marrowderived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity
16. Murine dendritic cells pulsed in vitro with tumor antigen induce tumor resistance in vivo
17. Dendritic cell vaccines for cancer immunotherapy
18. Cancer vaccines
19. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - A feasibility study
20. Detection of interleukin-12 (IL-12)-secreting cells in normal mice with enzyme-linked immunospot (ELISPOT) assay
21. Allogeneic peripheral blood progenitor cell transplantation in a murine model: Evidence for an improved graft-versus-leukemia effect
22. Peripheral T-cell tolerance as a tumor escape mechanism: Deletion of CD4+ T-cells specific for a monoclonal immunoglobulin idiotype secreted by a plasmocytoma
23. Idiotype-reactive T-cell subsets and tumor load in monoclonal gammopathies
24. Escape mechanisms in tumor immunity: A year 2000 update
25. Interleukin-10: A cytokine used by tumors to escape immunosurveilance
26. Idiotypic proteinpulsed adherent peripheral blood mononuclear cell-derived dendritic cells prime immune system in multiple myeloma
27. Generation of anti-idiotype immune responses following vaccination with idiotype-protein pulsed dendritic cells in myeloma
28. Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma
29. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: Immunological and clinical aspects
30. Thymic-independent T-cell regeneration occurs via antigen-driven expansion of peripheral T-cells resulting in a repertoire that is limited in diversity and prone to skewing
31. CD4+ T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells
32. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice
33. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8+ T cells
34. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type I, major histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses